S1533 National Landscape of Unplanned 30-Day Readmissions in Liver Transplant Patients Undergoing ERCP: Insights from National Readmission Database
Patel S, Nawaz A, Chaar A, Rizwan R, Mehta D, Aswath G, Khan H. S1533 National Landscape of Unplanned 30-Day Readmissions in Liver Transplant Patients Undergoing ERCP: Insights from National Readmission Database. The American Journal Of Gastroenterology 2024, 119: s1111-s1112. DOI: 10.14309/01.ajg.0001035500.60147.31.Peer-Reviewed Original ResearchS1627 ERCP Outcomes in Patients With Low Body Mass Index: A Propensity Score-Matched Study
Nawaz A, Bennett C, Chaar A, Hussain A, Khalid F, Hayat U, Singh K, Aswath G, Khan H. S1627 ERCP Outcomes in Patients With Low Body Mass Index: A Propensity Score-Matched Study. The American Journal Of Gastroenterology 2024, 119: s1185-s1185. DOI: 10.14309/01.ajg.0001035876.40979.9a.Peer-Reviewed Original ResearchS1534 National Landscape of Unplanned 30-Day Readmissions in Patients Undergoing ERCP: Insights from National Readmission Database
Patel S, Chaar A, Nawaz A, Rizwan R, Aswath G, Mehta D, Khan H. S1534 National Landscape of Unplanned 30-Day Readmissions in Patients Undergoing ERCP: Insights from National Readmission Database. The American Journal Of Gastroenterology 2024, 119: s1112-s1112. DOI: 10.14309/01.ajg.0001035504.17425.02.Peer-Reviewed Original ResearchS1414 Immunomodulator Therapy is Associated With Higher Incidence of Primary Sclerosing Cholangitis and Colorectal Cancer Compared to Biologic Therapy: A Propensity-Matched Cohort Study
Nawaz A, Shah A, Chaar A, Singh K, Aswath G, Khan H, John S. S1414 Immunomodulator Therapy is Associated With Higher Incidence of Primary Sclerosing Cholangitis and Colorectal Cancer Compared to Biologic Therapy: A Propensity-Matched Cohort Study. The American Journal Of Gastroenterology 2024, 119: s1012-s1012. DOI: 10.14309/01.ajg.0001035024.11002.ae.Peer-Reviewed Original ResearchS1413 Impact of Race on Clinical Outcomes in IBD Patients on Anti-TNF Monotherapy and Anti-TNF Combination Therapy With Immunomodulators: A Propensity-Matched Cohort Study
Nawaz A, Almasaid S, Shah A, Hussain A, Chaar A, Patel S, Khalid F, Hayat U, Singh K, Aswath G, Khan H. S1413 Impact of Race on Clinical Outcomes in IBD Patients on Anti-TNF Monotherapy and Anti-TNF Combination Therapy With Immunomodulators: A Propensity-Matched Cohort Study. The American Journal Of Gastroenterology 2024, 119: s1011-s1012. DOI: 10.14309/01.ajg.0001035020.13797.dd.Peer-Reviewed Original ResearchEndoscopic therapy for gastrointestinal angiodysplasia
Alhamid A, Aljarad Z, Chaar A, Grimshaw A, Hanafi I. Endoscopic therapy for gastrointestinal angiodysplasia. 2024, 2024: cd014582. PMID: 39297500, PMCID: PMC11411905, DOI: 10.1002/14651858.cd014582.Peer-Reviewed Original Research1003 COMPARISON OF THE INCIDENCE OF SPONTANEOUS BACTERIAL PERITONITIS AND RENAL ADVERSE EVENTS IN PATIENTS WITH CIRRHOSIS ON LACTULOSE VERSUS RIFAXIMIN THERAPY
Nawaz A, Kumar V, Chaar A, Hussain A, Kelita S, Aswath G, Khan H, John S. 1003 COMPARISON OF THE INCIDENCE OF SPONTANEOUS BACTERIAL PERITONITIS AND RENAL ADVERSE EVENTS IN PATIENTS WITH CIRRHOSIS ON LACTULOSE VERSUS RIFAXIMIN THERAPY. Gastroenterology 2024, 166: s-247. DOI: 10.1016/s0016-5085(24)01051-5.Peer-Reviewed Original ResearchMo1610 IMPACT OF OBESITY AND MORBID OBESITY ON HOSPITAL OUTCOMES OF PATIENTS ADMITTED WITH ALCOHOLIC HEPATITIS
Nawaz A, Chaar A, Hussain A, Aloysius M, Kumar V, Kelita S, Khan H, Aswath G, John S. Mo1610 IMPACT OF OBESITY AND MORBID OBESITY ON HOSPITAL OUTCOMES OF PATIENTS ADMITTED WITH ALCOHOLIC HEPATITIS. Gastroenterology 2024, 166: s-1057-s-1058. DOI: 10.1016/s0016-5085(24)02902-0.Peer-Reviewed Original Research257 IMPACT OF FRAILTY ON PER ORAL ENDOSCOPIC MYOTOMY(POEM): A NATIONAL DATABASE ANALYSIS
Nawaz A, Chaar A, Khaliq A, Kumar V, Aloysius M, Shah A, Khalid M, Subedi A, Suhail F, Kudaravalli P, Kelita S, Aswath G, Khan H. 257 IMPACT OF FRAILTY ON PER ORAL ENDOSCOPIC MYOTOMY(POEM): A NATIONAL DATABASE ANALYSIS. Gastroenterology 2024, 166: s-61-s-62. DOI: 10.1016/s0016-5085(24)00636-x.Peer-Reviewed Original ResearchSa1475 PREDICTORS OF 30-DAY READMISSION IN NECROTIZING PANCREATITIS: A POPULATION-BASED STUDY
Nawaz A, Hussain A, Chaar A, Khan H, Khaliq A, Avila P, Larsen M, Aswath G, Dai S, Arain M, Kouanda A. Sa1475 PREDICTORS OF 30-DAY READMISSION IN NECROTIZING PANCREATITIS: A POPULATION-BASED STUDY. Gastroenterology 2024, 166: s-466. DOI: 10.1016/s0016-5085(24)01539-7.Peer-Reviewed Original Research1007 NONSELECTIVE BETA BLOCKERS ARE BENEFICIAL IN PATIENTS WITH CIRRHOTIC ASCITES, AND NOT DELETERIOUS WITH SPONTANEOUS BACTERIAL PERITONITIS
Nawaz A, Kumar V, Chaar A, Kelita S, Khan H, Aswath G, John S. 1007 NONSELECTIVE BETA BLOCKERS ARE BENEFICIAL IN PATIENTS WITH CIRRHOTIC ASCITES, AND NOT DELETERIOUS WITH SPONTANEOUS BACTERIAL PERITONITIS. Gastroenterology 2024, 166: s-248-s-249. DOI: 10.1016/s0016-5085(24)01055-2.Peer-Reviewed Original ResearchSu1561 CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI). INSIGHT FROM THE NATIONAL INPATIENT SAMPLE.
Aboursheid T, Hijazi M, Albuni M, Sawaf B, Khokhlov L, Elfert K, Beran A, Abdalla M, Chaar A. Su1561 CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI). INSIGHT FROM THE NATIONAL INPATIENT SAMPLE. Gastroenterology 2024, 166: s-1640. DOI: 10.1016/s0016-5085(24)04230-6.Peer-Reviewed Original ResearchMo1345 ACUTE VASCULAR INTESTINAL DISEASE IN PATIENTS WITH END-STAGE RENAL DISEASE: A NATIONAL ANALYSIS
Rizwan R, Chaar A, Sehgal K, Richter T, Nawaz A, Patel S, Feuerstadt P. Mo1345 ACUTE VASCULAR INTESTINAL DISEASE IN PATIENTS WITH END-STAGE RENAL DISEASE: A NATIONAL ANALYSIS. Gastroenterology 2024, 166: s-1033. DOI: 10.1016/s0016-5085(24)02849-x.Peer-Reviewed Original ResearchMo1882 EFFECTIVENESS AND SAFETY OF ADVANCED THERAPIES IN IBD-PSC: A SYSTEMATIC REVIEW AND META-ANALYSIS
ELGamal M, Li D, Chaar A, Alahdab F, Grimshaw A, Al-Bawardy B. Mo1882 EFFECTIVENESS AND SAFETY OF ADVANCED THERAPIES IN IBD-PSC: A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastroenterology 2024, 166: s-1158-s-1159. DOI: 10.1016/s0016-5085(24)03121-4.Peer-Reviewed Original ResearchSa1898 RACIAL DISPARITIES IN PATIENTS HOSPITALIZED WITH CLOSTRIDIOIDES DIFFICILE INFECTION: A POPULATION-BASED STUDY
Chaar A, Rizwan R, Patel S, Sehgal K, Richter T, Nawaz A, Feuerstadt P. Sa1898 RACIAL DISPARITIES IN PATIENTS HOSPITALIZED WITH CLOSTRIDIOIDES DIFFICILE INFECTION: A POPULATION-BASED STUDY. Gastroenterology 2024, 166: s-569-s-570. DOI: 10.1016/s0016-5085(24)01783-9.Peer-Reviewed Original ResearchSu1009 RACIAL DISPARITIES IN ACUTE VASCULAR INTESTINAL DISEASES: A NATIONAL ANALYSIS
Sehgal K, Chaar A, Rizwan R, Richter T, Feuerstadt P. Su1009 RACIAL DISPARITIES IN ACUTE VASCULAR INTESTINAL DISEASES: A NATIONAL ANALYSIS. Gastroenterology 2024, 166: s-634-s-635. DOI: 10.1016/s0016-5085(24)01916-4.Peer-Reviewed Original ResearchFrailty is a predictor for worse outcomes in patients hospitalized with Clostridioides difficile infection
Chaar A, Yoo J, Nawaz A, Rizwan R, Agha O, Feuerstadt P. Frailty is a predictor for worse outcomes in patients hospitalized with Clostridioides difficile infection. Annals Of Gastroenterology 2024, 37: 442-448. PMID: 38974087, PMCID: PMC11226747, DOI: 10.20524/aog.2024.0898.Peer-Reviewed Original ResearchHospital Frailty Risk ScoreHealthcare resource utilizationHigher healthcare utilizationAdministrative billing dataPrimary diagnosis of CDIFrailty Risk ScoreNational Inpatient SampleHigher healthcare resource utilizationIntensive care unit admissionHealthcare utilizationClostridioides difficile</i> infectionFrailty statusDiagnosis of CDIRisk-stratify patientsHigher oddsClostridioides difficile infectionInpatient mortalityPerioperative risk assessmentHospital outcomesBilling dataRisk scoreInpatient SampleFrailtyAssessed differencesHealth implications